Immix Biopharma (IMMX) EBT (2021 - 2026)
Immix Biopharma (IMMX) reported EBT of -$10.1 million for Q1 2026, down 122.53% on a YoY basis from $44.8 million in Q1 2025, and up 5.52% sequentially from -$10.7 million in Q4 2025.
Immix Biopharma (IMMX) EBT (2021 - 2026) Analysis & Trends
Immix Biopharma (IMMX) has 6 years of EBT data on file, last reported at -$10.1 million in Q1 2026.
- For the quarter ending Q1 2026, EBT fell 122.53% year-over-year to -$10.1 million; the trailing twelve-month figure through Mar 2026 stood at -$35.0 million (down 4542.14% YoY), and the FY2025 full-year result was -$29.4 million, down 1806.04% from the prior year.
- EBT rose to -$10.1 million in Q1 2026, from -$10.7 million in the prior quarter.
- In the past five years, EBT ranged from a high of $15.3 million in Q4 2024 to a low of -$10.7 million in Q4 2025.
- A 5-year average of -$3.8 million and a median of -$4.4 million in 2024 frame the typical range for EBT.
- Across the five-year window, EBT sank 654.03% in 2022 and surged 397.51% in 2024, its largest moves.
- Tracing IMMX's EBT over 5 years: stood at -$3.8 million in 2022, then plunged by 35.65% to -$5.1 million in 2023, then surged by 397.51% to $15.3 million in 2024, then sank by 169.72% to -$10.7 million in 2025, then climbed by 5.52% to -$10.1 million in 2026.
- Business Quant data shows IMMX's EBT at -$10.1 million in Q1 2026, -$10.7 million in Q4 2025, and -$7.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.31 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 259.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 438.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -453.82 Mn |
| 10 | Immix Biopharma | 473.68 Mn | 473.68 Mn | - | -10.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -10.09 Mn |
| Dec 31, 2025 | -10.68 Mn |
| Sep 30, 2025 | -7.58 Mn |
| Jun 30, 2025 | -6.61 Mn |
| Mar 31, 2025 | -4.53 Mn |
| Dec 31, 2024 | 15.31 Mn |
| Sep 30, 2024 | -7.14 Mn |
| Jun 30, 2024 | -4.40 Mn |
| Mar 31, 2024 | -5.32 Mn |
| Dec 31, 2023 | -5.15 Mn |
| Sep 30, 2023 | -4.34 Mn |
| Jun 30, 2023 | -3.59 Mn |
| Mar 31, 2023 | -2.49 Mn |
| Dec 31, 2022 | -3.79 Mn |
| Sep 30, 2022 | -1.53 Mn |
| Jun 30, 2022 | -1.56 Mn |
| Mar 31, 2022 | -1.33 Mn |
| Dec 31, 2021 | -22.75 Mn |
| Sep 30, 2021 | -401,928.00 |
| Jun 30, 2021 | -207,030.00 |